{
    "organizations": [],
    "uuid": "16e70729ee8445f74605c614b197b7577d11f97a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-checkmate-pharmaceuticals-announce/brief-checkmate-pharmaceuticals-announces-start-of-phase-1b-trial-of-cmp-001-in-combination-with-anti-pd-l1-immunotherapy-in-anti-pd-1-pd-l1-resistant-advanced-non-small-cell-lung-cancer-idUSASC09WZP",
    "ord_in_thread": 0,
    "title": "BRIEF-Checkmate Pharmaceuticals Announces Start Of Phase 1B Trial Of CMP-001 In Combination With Anti-Pd-L1 Immunotherapy In Anti-Pd-1/Pd-L1 Resistant Advanced Non-Small Cell Lung Cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " CHECKMATE PHARMACEUTICALS:\n* CHECKMATE PHARMACEUTICALS ANNOUNCES START OF PHASE 1B TRIAL OF CMP-001 IN COMBINATION WITH ANTI-PD-L1 IMMUNOTHERAPY IN ANTI-PD-1/PD-L1 RESISTANT ADVANCED NON-SMALL CELL LUNG CANCER Source text for Eikon: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-04-24T19:12:00.000+03:00",
    "crawled": "2018-04-25T14:28:12.009+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "checkmate",
        "pharmaceutical",
        "checkmate",
        "pharmaceutical",
        "announces",
        "start",
        "phase",
        "1b",
        "trial",
        "combination",
        "immunotherapy",
        "resistant",
        "advanced",
        "cell",
        "lung",
        "cancer",
        "source",
        "text",
        "eikon"
    ]
}